Why is immunogenicity a concern for biologics and what study designs monitor it during development?

Prepare for the Drug Discovery and Healthcare Systems Test. Access flashcards and multiple-choice questions with hints and explanations. Ace your exam with our comprehensive resources!

Immunogenicity is a concern because biologics are protein-based therapies that the immune system may recognize as foreign. When patients develop anti-drug antibodies, these can bind the therapeutic, potentially neutralize its activity, or speed up its clearance. That can reduce efficacy and raise safety risks, such as infusion reactions or hypersensitivity. Because of these potential consequences, development programs include immunogenicity assessment across the entire pipeline.

Designs to monitor immunogenicity span both preclinical and clinical stages. In preclinical work, animals are evaluated for antibody responses to flag candidates with higher immunogenic risk. In humans, structured immunogenicity programs use validated assays to detect anti-drug antibodies and, separately, neutralizing antibodies at multiple timepoints—often including baseline and several post-dose visits—while integrating this data with pharmacokinetic and safety findings. This approach helps determine whether immune responses affect drug exposure or clinical outcomes and informs dosing decisions, monitoring plans, and risk mitigation strategies.